http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NO-992526-L

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D501-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D501-36
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-546
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D501-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D501-36
filingDate 1999-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d1875c4689cd217b3f52f4b6f825e05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb1bf5bdec1d00bf094b27f0f5bc7e41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6ff2ba41694a1afb732421d68d51ada
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f2ee7e338cf54158222b85f71ff71da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45d0c18feb63d970deec3e29f841afb4
publicationDate 1999-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber NO-992526-L
titleOfInvention Cephalosporin derivatives
abstract Cephem derivatives of the general formula V /? CH2-S-Q COOR1 wherein Q is an optionally substituted pyridinium group connected to the sulfur atom via a ring carbon atom; X is halogen; Y is hydrogen or halogen; L1 is a furan group, a thiophene group, a C2-C10 alkyl group, or a C2-C10 alkyl group interrupted by one or more groups independently selected from vinyl, S, SO, SO2, SO2 NH, H or xNxri / H on is O or 1; A is CO 2 H, PO 3 H 2, SO 3 H or tetrazole; and R 1 is hydrogen or a carboxyl protecting group; and pharmaceutically acceptable salts and / or prodrugs thereof. The derivatives are gram-positive antibacterial agents particularly suitable for the treatment of diseases caused by methicillin-resistant Staphylococcus aureus (MRSA).
priorityDate 1996-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491140
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414392184
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456171974
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6087
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414305203
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397365
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425193155
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4989215
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8030
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393356
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID783
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419526944
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8029

Total number of triples: 35.